focus -WSS

focus

author：explore 2025-09-06 02:16:21 - browse：2831

Principal Deputy FDA Commissioner Janet Woodcock Stefani Reynolds/The New York Times via AP

WASHINGTON — Principal Deputy FDA Commissioner Janet Woodcock will retire early next year from the Food and Drug Administration after helping steer the agency through an historic period of medical advances during nearly four decades in key leadership positions, she confirmed to STAT Thursday.

Woodcock, a doctor with a chemistry degree, joined FDA in 1986 at its biologics center, where she oversaw the approval of the first biotechnology-based treatments for multiple sclerosis and cystic fibrosis. In 1994, she was named director of the drug center, where she played a key role in guiding some of the most impactful changes to the regulation of medicine, according to Trump administration FDA Commissioner Scott Gottlieb.

Woodcock envisioned that antibody drugs would become a backbone of therapy and created a more predictable regulatory path for their review and approval, Gottlieb said. She presided over a major expansion and modernization of the generic drug program, standardizing reviews in a way that allowed the industry to become safer and more robust, and crafted the reform of over-the-counter drug reviews.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： ADCs take center stage as promising cancer treatments

leisure time

entertainment

WSS

Roche acquires Telavant from Roivant, adding experimental IBD treatment

STAT Readout: Friday, Oct. 20 biotech updates

Ozempic cut risk of death in diabetes patients with chronic kidney disease

ADCs take center stage as promising cancer treatments

Beyond aggravation: Constipation is an American epidemic

Richard Slayman had a rejection episode of his pig kidney before leaving hospital

Wikipedia

focus

focus

Bright Health sells Medicare Advantage business to Molina

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

BioMarin wins approval for gene therapy to treat hemophilia A

Pharma’s losing bet in New Jersey

Medicare details structure of new drug price negotiation program

Asahi Kasei to buy Calliditas, picking up kidney disease drug

Tori Bowie and the unacceptable rates of Black maternal death

Beyond aggravation: Constipation is an American epidemic

Apple is now the first public company to be valued at $3 trillion

Pharma’s losing bet in New Jersey

focus

Clinicians often fail to acknowledge the pain caused by long Covid

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

STAT Summit: Meghan O’Rourke on making chronic illness visible

Decentralized clinical trials need collaboration to achieve wider use

Decentralized clinical trials need collaboration to achieve wider use

Hospitals need to get ahead of regulations on climate change

leisure time

entertainment

knowledge

focus